RANGER II SFA: By Boston Scientific

(A Clinical Trial for the treatment of peripheral artery disease in legs using drug coated Balloon)

This is a randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries.

TOBA II BTK: By Intact Vascular

(A Clinical Trial for New Peripheral Revascularization Treatment Option Below the Knee using TACK Endovascular System)

This is a prospective, multi-center study designed to investigate the safety and efficacy of the Tack Endovascular System in patients with peripheral artery disease (PAD) below the knee joint.

COPPER-A Study: By The Horizons International Peripheral Group

(A Clinical Trial for the treatment of peripheral artery disease in legs by using drug coated Catheter)

The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal stenoses and occlusions.

PB1046-PT-CL-0003-P1.5: By PhaseBio Pharmaceuticals Inc.

(A Phase II Heart Failure Study in Patients with Reduced Ejection Fraction)

A Phase 2a study to assess the safety, tolerability and PK response and explore the PD response following 4 weeks of once weekly subcutaneous injections of PB1046 in adult subjects with stable heart failure with reduced Ejection Fraction.

TOBA II: By Intact Vascular

(A Clinical Trial for New Peripheral Revascularization Treatment Option using TACK Endovascular System)

(Enrollment Closed)

This is a prospective, multi-center study designed to investigate the safety and efficacy of the Tack Endovascular System in patients with peripheral artery disease (PAD) above the knee.

(CREDENCE): By National Heart Lung and Blood Institute (NHLBI)

(Study to evaluate diagnostic procedures of a new onset coronary artery disease)

This study is to evaluate and compare the role of currently available diagnostic modalities in the treatment of new onset coronary artery disease.

COMMANDER HF Study: By Janssen

(Study to evaluate addition of a blood thinner Xarelto in current treatment regimen for Heart Failure Patients)

The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with chronic heart failure and significant coronary artery disease following a recent hospitalization for exacerbation (worsening) of heart failure. Site is currently enrolling patients in this study.

(PARAGON-HF): By Novartis

(Study to evaluate efficacy and safety of a new Heart Failure Drug Entresto in comparison to valsartan)

This study is to evaluate the efficacy and safety of valsartan/sacubitril (Entresto) compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction. Site is currently enrolling patients in this study.

ORBIT II-AF REGISTRY: By Janssen

(Outcomes Registry for Better Informed Treatment of Atrial Fibrillation)

(Enrollment Closed)

The primary objective of this study is to evaluate the safety of various oral anticoagulant agents in patients with atrial fibrillation, when these agents are administered as standard of care. This study is currently open for enrollment.

ANTELOPE REGISTRY: By TriReme

(Assessment to treat Complex Plaques in the Heart with a Balloon Catheter)

This is an observational Study collecting data on commercial cases in which the Glider PTCA Balloon Catheter is used in accordance with the instructions for use. This study is currently open for enrollment.

BIOFLOW-V: By Biotronik

(A Study to evaluate effectiveness and safety of a drug eluting stent to treat plaques in the blood vessels of the heart)

(Enrollment Closed)

To assess the safety and efficacy of the Orsiro Sirolimus (Drug) Eluting Coronary Stent in the treatment of subjects with significant coronary artery disease compared to the Xience coronary stent system.

BIOHELIX-I: By Biotronik

(A Stent Study to treat coronary artery disease)

(Enrollment Closed)

The BIOHELIX-I trial is a prospective, nonrandomized, multicenter, investigational device exemption (IDE) study that will evaluate the safety and performance of BIOTRONIK’s PRO-Kinetic Energy coronary stent system in patients with symptomatic, ischemic heart disease. More than 300 patients will be enrolled in this study.

BIOFLEX-I: By Biotronik

(A Stent Study to treat peripheral artery disease)

(Enrollment Closed)

The BIOFLEX-I is a prospective, nonrandomized, multicenter, investigational device exemption (IDE) study that will evaluate safety and performance of BIOTRONIK’s Astron and Astron Pulsar stents for the treatment of peripheral artery disease.

CANTOS Trial: By Novartis

(Use of anti inflammatory drug canakinumab to prevent future heart attack)

(Enrollment Closed)

The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) will test whether reducing inflammation among men and women who have had a prior heart attack can reduce the risk of another cardiovascular event happening in the future. The enrollment is this study is permanently closed, site is currently conducting follow ups on already enrolled patients.